Tenax Therapeutics, INC Form 4 insider transactions

Tenax Therapeutics' Chief Medical Officer, Rich Stuart, reports stock option grants and holdings through irrevocable trusts.

Tenax Therapeutics director Gerald T. Proehl acquired 100,000 stock options and disposed of 1,667 common shares on December 10, 2024.

Tenax Therapeutics insider Robyn Hunter was granted stock options to purchase 100,000 shares of common stock at an exercise price of $5.94.

Tenax Therapeutics CEO, Christopher Thomas Giordano, was granted stock options on December 10, 2024, with vesting schedules extending to 2028.

Tenax Therapeutics has adjusted previously reported stock option grants and share counts to reflect stock splits that occurred in 2023 and 2024.

A recent filing details stock options and warrants granted to Michael H. Davidson of Tenax Therapeutics, including pre-funded warrants tied to the company's Phase 3 study results.

June Sherie Almenoff, a director at Tenax Therapeutics, acquired 100,000 stock options on December 10, 2024.

Director Gerald T. Proehl acquired common stock and warrants of Tenax Therapeutics through a private placement, according to a Form 4 filing.

Director Michael H. Davidson purchased shares, pre-funded warrants, and warrants of Tenax Therapeutics in a private placement on August 8, 2024.

Chief Medical Officer of Tenax Therapeutics, Stuart Rich, reports the acquisition of stock options and adjustments to previously reported holdings due to stock splits.

CEO Christopher Giordano reports the acquisition of stock options in Tenax Therapeutics, Inc.